Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Affymetrix 500K SNP Chip Users (US)(?)

Council Members in this Study Group: 50

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

What is a GLG Leader?
Gregory Khitrov, PhD, Director of Personalized Medicine Program, MOUNT SINAI SCHOOL OF MEDICINE Gregory Khitrov, PhD
Director of Personalized Medicine Program
MOUNT SINAI SCHOOL OF MEDICINE

Greg Khitrov, PhD, is the Director of Life Sciences Technology Center at the Institute for Personalized Medicine, Director of Biobank and an Assistant Professor of Medicine at the Mount Sinai School of Medicine in New York. He has expertise in molecular biology; proteomics; and laboratory automation...


1 recent event(s)

Related Study Groups

GLG NewsSMAnalyses by this Study Group's Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
generic biotech drugs | 02-21-2007
Analysis of: Bill Would Allow Copying of Biotech Drugs | www.nytimes.com
Author: GLG Expert Contributor

Long feared option for FDA. The argument that biologics are "so complicated" needs another look. May be after years of biologics we learned it is not that specific nor that complicated. This decision may affect the price of small molecules and biologics and seems a breakthrough in thinking. Generic...

View All GLG News by members of this Study Group

GLG InstituteSM Seminars with this Study Group's Leaders(?)

 

Recent Seminars

GLGi: Genotyping Technologies
New York, 04-26-2007

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Academic Institution*
  • Research Foundation
  • Pharmaceuticals Manufacturer
  • Consultancy, Pharma-Focused
  • Lab, Academic Medical Center

Most Common Job Types:

  • Director
  • Physician - Attending Physician
  • Research Scientist
  • Professor
  • Physician - Director
  • Physician - Department Chair
  • Researcher

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics